FCE 22891: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6918147 |
| SCHEMBL ID | 9799600 |
| MeSH ID | M0123232 |
| Synonym |
|---|
| fce-22891 |
| fce 22891 |
| acetoxymethyl (5r,6s)-2-carbamoyloxymethyl-6-((1r)-hydroxyethyl)-2-penem-3-carboxylate |
| brn 4723315 |
| 4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-6-(1-hydroxyethyl)-7-oxo-, (acetyloxy)methyl ester, (5r-(5-alpha,6-alpha(r*)))- |
| unii-f975h7yqx9 |
| f975h7yqx9 , |
| ritipenem acetoxymethyl ester [mi] |
| 4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-6-(1-hydroxyethyl)-7-oxo-, (acetyloxy)methyl ester, (5r-(5.alpha.,6.alpha.(r*)))- |
| 4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 3-(((aminocarbonyl)oxy)methyl)-6-((1r)-1-hydroxyethyl)-7-oxo-, (acetyloxy)methyl ester, (5r,6s)- |
| (+)-ritipenem acoxil |
| fce22891 |
| SCHEMBL9799600 |
| Q27277840 |
| (acetyloxy)methyl (5r,6s)-3-[[(aminocarbonyl)oxy]methyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate |
| DTXSID101101569 |
FCE 22891 is a prodrug of the penem antibiotic FCE 22101. It is suitable for oral administration.
| Excerpt | Reference | Relevance |
|---|---|---|
| "FCE 22891 is a prodrug of the penem antibiotic FCE 22101 and is suitable for oral administration. " | ( Pharmacokinetics of [14C]FCE 22891, a penem antibiotic, following oral administration to healthy volunteers. Boobis, A; Davies, D; Efthymiopoulos, C; Sassella, D; Strolin Benedetti, M, 1992) | 2.03 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Intravenously administered FCE 22101 at a dose of 250 mg gave peak plasma concentrations of about 12 mg/l and the plasma half-life was about 60 min." | ( Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101. Burman, LA; Cassinelli, G; Corigli, R; Dornbusch, K; Franceschi, G; Norrby, SR; Sassella, D, 1990) | 0.51 |
| " The proposed method was applied to the pharmacokinetic studies of an active metabolite and open-ring metabolites after oral administration of a penem antibiotic, FCE22891, in dogs." | ( Simultaneous determination of an active metabolite and open-ring metabolites by high performance liquid chromatography and pharmacokinetic studies of a penem antibiotic, FCE22891, in dogs. Banno, K; Imado, N; Maki, T; Matsuoka, M; Sato, T, 1998) | 0.3 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "min/L giving an absolute bioavailability for FCE 22101 of 32%." | ( Pharmacokinetics and metabolism of FCE 22101 following its administration as the oral pro-drug FCE 22891. Lewis, DA; Lovering, AM; MacGowan, AP; Reeves, DS, 1992) | 0.5 |
| " The pharmacokinetics of the penem were linear, and its bioavailability after oral administration was 42 +/- 11%." | ( Pharmacokinetics of FCE 22891, a new oral penem. Borner, K; Deppermann, KM; Hampel, B; Koeppe, P; Lode, H; Saathoff, A, 1990) | 0.6 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "9% following oral and intravenous dosing respectively." | ( The pharmacokinetics and tissue penetration of FCE 22101 following intravenous and oral administration. Andrews, JM; Ashby, JP; Wallbridge, D; Webberley, JM; Wise, R, 1988) | 0.27 |
| " It can be seen both in untreated controls and dosed animals." | ( Urinary bladder hyperplasia in the rat: non-specific pathogenetic considerations using a beta-lactam antibiotic. Brughera, M; Dayan, AD; Iatropoulos, MJ; Mazue, G; Newman, AJ; Scampini, G, 1994) | 0.29 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 11 (68.75) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.47) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (21.05%) | 5.53% |
| Reviews | 1 (5.26%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (73.68%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||